A year on Mounjaro\u00ae is the data point that reshaped the GLP-1 landscape. SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed 20.9 percent mean weight loss at week 72 on tirzepatide 15 mg, the highest published result for a non-surgical obesity intervention. The dual GIP\/GLP-1 mechanism delivers what GLP-1 alone cannot.<\/p>\n
Realistic 12 month results sit at 17 to 21 percent of starting body weight for adherent patients on 10 mg or 15 mg. For a 220 pound starting weight that means 37 to 46 pounds gone. Some responders push 24 to 26 percent; others stall earlier at 12 to 14 percent.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
The mean 1 year weight loss on Mounjaro is 17 to 21 percent of starting body weight for adherent patients on 10 mg or 15 mg.<\/strong> That works out to 37 to 46 pounds at 220 pounds or 46 to 57 pounds at 270 pounds.<\/p>\n Quick Answer: Typical 1 year loss on Mounjaro is 17 to 21 percent of starting body weight<\/p>\n SURMOUNT-1 (Jastreboff et al. 2022 NEJM) is the headline dataset, enrolling 2,539 adults on tirzepatide for 72 weeks. Mean weight loss at week 72 was 15 percent on 5 mg, 19.5 percent on 10 mg, and 20.9 percent on 15 mg. At week 52 the numbers were about 12, 18, and 19 percent respectively.<\/p>\n The trial standard deviation was wide. About 50 percent of patients on 15 mg lost 20 percent or more; 9 percent lost less than 5 percent. Response varies widely even among adherent patients, with strong responders and partial responders pulling the mean.<\/p>\n A 2024 real-world cohort from Truveta on 6,000 plus tirzepatide users showed about 13 percent loss at 12 months among adherent patients (52 percent adherence). The gap between real-world and trial averages reflects dose timing, missed injections, and supply gaps.<\/p>\n The 1 year plateau on Mounjaro usually starts between week 55 and 68 and represents the point where adaptive thermogenesis matches the dual agonist appetite effect.<\/strong> The scale stops moving for weeks at a time, with body composition still slowly improving.<\/p>\n SURMOUNT-1 weight loss curves show the steepest slope from weeks 4 to 36, gentler from week 36 to 56, and near-flat from week 56 to 72. The plateau is biological and resistant to aggressive deficit attempts.<\/p>\n Sumithran and Proietto 2014 in Obesity journal documented appetite hormone changes after weight loss. Ghrelin, leptin, and other markers stay shifted toward weight regain for at least 12 months after major loss. Tirzepatide blunts this defense more effectively than semaglutide but does not eliminate it.<\/p>\n Patients who keep losing past month 12 usually share two traits: consistent resistance training and high protein intake. Without those, the plateau holds firmly and slight regain creeps in by month 14 to 15.<\/p>\n Metabolic improvements at year 1 on Mounjaro are often more clinically meaningful than the weight loss itself.<\/strong> A1c reductions of 2.0 to 2.5 points in diabetic patients, systolic blood pressure drops of 7 to 10 mmHg, and triglyceride reductions of 30 to 40 percent are typical.<\/p>\n SURPASS-2 (Frias et al. 2021 NEJM), the head-to-head against semaglutide in 1,879 type 2 diabetes patients, showed tirzepatide 15 mg produced 2.3 percentage point A1c reductions versus 1.86 for semaglutide. Weight loss was 11.2 kg versus 5.7 kg at 40 weeks.<\/p>\n SURMOUNT-OSA (Malhotra et al. 2024 NEJM) showed tirzepatide significantly improved obstructive sleep apnea severity. FDA approval for OSA followed in December 2024. Most OSA improvements stabilized by month 12.<\/p>\n SURPASS-CVOT, the cardiovascular outcomes trial, is ongoing through 2027 to confirm the mortality and event reduction expected based on weight and metabolic improvements. Early signal is favorable.<\/p>\n Stopping Mounjaro at 1 year typically leads to regaining about half of the lost weight within 12 months.<\/strong> This is from SURMOUNT-4 (Aronne et al. 2024 JAMA), the discontinuation extension of the SURMOUNT program.<\/p>\n SURMOUNT-4 randomized 670 patients after a 36 week lead-in on tirzepatide to either continue or switch to placebo for 52 weeks. The continuation group lost an additional 5.5 percent. The placebo group regained 14 percent of body weight, which represented about half of the prior loss.<\/p>\n The biological mechanism is appetite hormone shift, the same as with semaglutide but more pronounced because of the dual receptor activation. When tirzepatide leaves the system, ghrelin rebounds and satiety signaling drops within 2 to 3 weeks.<\/p>\n Practical implication: Mounjaro at 1 year should be viewed like a chronic disease medication, ongoing rather than time-limited. Many providers try lower maintenance doses, 5 mg or 7.5 mg, after the loss phase to preserve results at lower cost and side effect burden.<\/p>\n Mounjaro outperforms Wegovy at 1 year by 4 to 6 percentage points.<\/strong> SURMOUNT-1 showed 20.9 percent loss at week 72 on tirzepatide 15 mg versus 14.9 percent for semaglutide in STEP 1, both with 1,900+ patient samples.<\/p>\n SURMOUNT-5, the first direct head-to-head between tirzepatide and semaglutide in obesity, reported in 2025 confirmed the tirzepatide advantage. Final numbers showed roughly 20 percent versus 14 percent at 72 weeks.<\/p>\n For 220 pounds starting weight, that translates to 33 pounds on Wegovy versus 46 pounds on Mounjaro at 12 months. Side effect profiles are similar; the main differentiator is efficacy at matched time horizons.<\/p>\n The dual GIP\/GLP-1 mechanism explains most of the difference. GIP modulates satiety and fat metabolism in ways that complement GLP-1 activity. TrimRx’s personalized treatment plan includes both options.<\/p>\n Key Takeaway: Tirzepatide outperforms semaglutide by about 6 percentage points at 1 year<\/p>\n Real-world year 1 results on Mounjaro are notably lower than SURMOUNT-1 trial averages, mostly because adherence drops over the year.<\/strong> Trial conditions provide free medication, structured support, and monitoring that translate to better outcomes.<\/p>\n The 2024 Truveta cohort reported 52 percent adherence at 12 months on tirzepatide, slightly higher than the 41 percent reported for semaglutide. Among adherent patients, mean weight loss was about 13 percent. Among all prescribed patients including dropouts, the figure was about 8 percent.<\/p>\n Cost and supply issues drive most discontinuations. Mounjaro shortages in 2022 and 2023 forced switches and gaps that interrupted progress for many patients. Insurance coverage for Zepbound\u00ae (the obesity formulation) has expanded but remains uneven.<\/p>\n Compounded tirzepatide platforms like TrimRx can sidestep some supply and cost issues. Brand-name access has improved in 2025 and 2026, but the price gap remains significant for cash-pay patients. The free assessment quiz is the standard entry point.<\/p>\n The standard protocol after a successful year 1 on Mounjaro is continued therapy at the maintenance dose, with optional dose reduction if weight is stable and side effects are bothersome.<\/strong> SURMOUNT-4 extension data supports continued dosing.<\/p>\n A common shift at month 12 is dropping from 15 mg to 10 mg or even 7.5 mg, then watching for 3 months. If weight stays flat at the lower dose, that becomes the long-term maintenance dose. If regain starts within 8 to 12 weeks, the prior dose is reinstated.<\/p>\n Lifestyle work matters more in year 2 than year 1. The weight is off, the medication is doing less of the heavy lifting, and habits become the primary driver. Resistance training, sleep, protein, and step count are the levers that hold the result.<\/p>\n Lab monitoring at month 12 typically includes A1c, lipid panel, kidney function, liver enzymes, and vitamin B12. TrimRx’s personalized treatment plan covers annual labs and maintenance dose adjustments.<\/p>\n Mounjaro has 2 to 3 year safety data from SURMOUNT and SURPASS programs.<\/strong> The safety profile is strong with thyroid C-cell tumors (animal data only, no clear human signal), pancreatitis (under 0.5 percent), and gallbladder disease (about 3 percent) as the main flagged risks.<\/p>\n The SURMOUNT and SURPASS programs combined include over 15,000 patients with longer-term follow-up still accruing. Serious adverse events were similar between tirzepatide and comparator groups. Discontinuation due to adverse events was about 6 percent.<\/p>\n Long-term concerns include muscle mass loss with prolonged calorie deficit, sarcopenia in older patients, and the unknowns of decade-long dual agonist exposure. Tirzepatide has been on the market since May 2022, so the longest-running real-world data is about 4 years.<\/p>\n Annual monitoring is the standard practice. A1c, lipids, kidney function, liver enzymes, and vitamin B12 cover most of the surveillance. DEXA every 1 to 2 years to track body composition is increasingly common for patients on long-term therapy.<\/p>\n Bottom line: Long-term cardiovascular and diabetes outcomes still being studied (SURPASS-CVOT ongoing)<\/p>\n Sixty pounds in 1 year is achievable for patients starting above 280 pounds, where 60 pounds represents about 21 percent body weight loss. SURMOUNT-1 had about 50 percent of patients on 15 mg lose 20 percent or more, which covers 60 pounds for many higher starting weights.<\/p>\n SURMOUNT-4 (Aronne 2024 JAMA) showed about half of weight regained within 12 months of stopping. A patient who lost 45 pounds typically regains 22 to 25 pounds in the year after stopping without tirzepatide therapy.<\/p>\n Long-term safety data from SURMOUNT and SURPASS through 2 to 3 years shows a strong safety profile. Annual monitoring is the standard practice. The thyroid tumor signal remains animal-only with no clear human evidence to date.<\/p>\n No, but weight loss usually plateaus between months 14 and 18. Therapy continues to maintain the lost weight and deliver metabolic protection. New loss after the plateau is uncommon without dose changes or adjunct interventions.<\/p>\n Many providers move from 15 mg down to 10 mg or 7.5 mg after the initial loss phase for long-term maintenance. The lower dose preserves most of the weight loss while reducing side effects and cost.<\/p>\n Most patients who want to keep the weight off stay on some GLP-1 or dual agonist long-term. Obesity is increasingly framed by AACE and ADA guidelines as a chronic condition with pharmacotherapy as ongoing rather than time-limited.<\/p>\n For most patients, yes. A1c typically drops 2.0 to 2.5 percentage points in diabetic patients, blood pressure falls 7 to 10 mmHg, triglycerides drop 30 to 40 percent, and inflammatory markers like hs-CRP often improve. These changes match SURPASS and SURMOUNT data.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" A year on Mounjaro is the data point that reshaped the GLP-1 landscape. SURMOUNT-1 (Jastreboff et al.<\/p>\n","protected":false},"author":11,"featured_media":93162,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Mounjaro Results After 1 Year: Realistic Weight Loss Expectations","_yoast_wpseo_metadesc":"A year on Mounjaro is the data point that reshaped the GLP-1 landscape. SURMOUNT-1 (Jastreboff et al.","_yoast_wpseo_focuskw":"mounjaro results after","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[11],"tags":[],"class_list":["post-90269","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mounjaro"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90269"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90269\/revisions"}],"predecessor-version":[{"id":91686,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90269\/revisions\/91686"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93162"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What Does the Year 1 Plateau Look Like?<\/h2>\n
How Do Year 1 Metabolic Results Compare to Weight Results?<\/h2>\n
What Happens If You Stop Mounjaro at 1 Year?<\/h2>\n
How Does Mounjaro Compare to Wegovy\u00ae at 1 Year?<\/h2>\n
What Real-world Year 1 Results Look Like<\/h2>\n
What Does the Year 1 Protocol Look Like for Year 2?<\/h2>\n
Is Mounjaro Safe for Long-term Use?<\/h2>\n
FAQ<\/h2>\n
Can You Lose 60 Pounds in 1 Year on Mounjaro?<\/h3>\n
How Much Weight Do You Regain After Stopping Mounjaro?<\/h3>\n
Is Mounjaro Safe to Take for Years?<\/h3>\n
Does Mounjaro Stop Working After a Year?<\/h3>\n
What’s the Best Dose for Long-term Mounjaro Maintenance?<\/h3>\n
Do You Need to Be on Mounjaro Forever?<\/h3>\n
Will My Labs Improve by 1 Year on Mounjaro?<\/h3>\n